Effect of Molecular Disease Subsets on Disease-Free Survival in Randomized Adjuvant Chemotherapy Trials for Estrogen Receptor–Positive Breast Cancer
Pusztai L, Broglio K, Andre F, Symmans WF, Hess KR, Hortobagyi GN. Effect of Molecular Disease Subsets on Disease-Free Survival in Randomized Adjuvant Chemotherapy Trials for Estrogen Receptor–Positive Breast Cancer. Journal Of Clinical Oncology 2008, 26: 4679-4683. PMID: 18662965, DOI: 10.1200/jco.2008.17.2544.Peer-Reviewed Original ResearchConceptsDisease-free survivalER-positive breast cancerAdjuvant chemotherapy trialsProportion of patientsBreast cancerChemotherapy trialsRS patientsEstrogen receptor-positive breast cancerRandomized adjuvant chemotherapy trialReceptor-positive breast cancerFuture adjuvant studiesProportion of casesTwo-arm clinical trialChemotherapy decreasesMolecular diagnostic testsAdjuvant chemotherapyEndocrine therapyAdjuvant studiesDisease subsetsPositive cancersClinical trialsDFS estimatesRisk groupsEstrogen receptorMolecular subtypesEstrogen Receptor Expression and Efficacy of Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis
Andre F, Broglio K, Roche H, Martin M, Mackey JR, Penault-Llorca F, Hortobagyi GN, Pusztai L. Estrogen Receptor Expression and Efficacy of Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis. Journal Of Clinical Oncology 2008, 26: 2636-2643. PMID: 18509176, DOI: 10.1200/jco.2007.14.9146.Peer-Reviewed Original ResearchConceptsER-negative patientsER-positive patientsRisk of recurrenceDocetaxel therapyER expressionER statusPooled analysisBreast cancerNode-positive breast cancerCox proportional hazards modelAdjuvant chemotherapy trialsDisease-free survivalEfficacy of docetaxelEstrogen receptor expressionPositive breast cancerRisk of deathRandomized clinical trialsProportional hazards modelAdjuvant chemotherapyAdjuvant docetaxelChemotherapy trialsOverall survivalDocetaxel efficacyRandomized trialsClinical variables